{"text": "A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO AND ACTIVE COMPARATOR CONTROLLED , PARALLEL , STUDY TO EVALUATE THE GLUCOSE - LOWERING EFFICACY , LIPID - ALTERING EFFICACY , SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "35.037403"}
{"text": "A PHASE 1 , PLACEBO - CONTROLLED , RANDOMIZED TRIAL TO ACCESS THE SAFETY , TOLERABILITY , PHARMACOKINETICS , AND PHARMACODYNAMICS OF MULTIPLE IV DOSES OF PF-05231023 IN OBESE HYPERLIPIDEMIC ADULT SUBJECTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS ON A BACKGROUND OF ATORVASTATIN ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "37.830673"}
{"text": "Diabetes Care 35:S11-S63 CrossRef .Inzucchi SE , Bergenstal RM , Buse JB et al ( 2012 )Management of hyperglycaemia in type 2 diabetes : a patient - centered approach .", "label": "", "metadata": {}, "score": "39.974346"}
{"text": "A PHASE II , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , PARALLEL GROUP STUDY , EVALUATING THE EFFICACY AND SAFETY OF RO4607381 OVER A 24-WEEK PERIOD IN PATIENTS WITH CHD OR A CHD RISK EQUIVALENT .", "label": "", "metadata": {}, "score": "41.020557"}
{"text": "Diabetes Obes Metab 9:194 - 205 PubMed CrossRef .Nauck MA , del Prato S , Meier JJ et al ( 2011 )Dapagliflozin versus glipizide as add - on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin : a randomized , 52-week , double - blind , active - controlled noninferiority trial .", "label": "", "metadata": {}, "score": "42.65779"}
{"text": "This study will evaluate the efficacy , safety , tolerability , and pharmacokinetics of oral GK Activator ( 2 ) , compared to placebo , in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "43.43342"}
{"text": "This study will evaluate the efficacy , safety , tolerability , and pharmacokinetics of oral GK Activator ( 2 ) , compared to placebo , in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "43.43342"}
{"text": "PubMed View Article .Kodama S , Saito K , Yachi Y , Asumi M , Sugawara A , Totsuka K , Saito A , Sone H : Association between serum uric acid and development of type 2 diabetes .", "label": "", "metadata": {}, "score": "44.698784"}
{"text": "A PLACEBO - CONTROLLED , RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP , DRUG INTERACTION STUDY TO EVALUATE THE SAFETY , TOLERABILITY , AND EFFECT ON ATORVASTATIN PHARMACOKINETICS OF ETC-1002 ADDED TO ATORVASTATIN 10 MG / DAY IN SUBJECTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "44.70794"}
{"text": "A PHASE 2 RANDOMIZED , DOUBLE - BLIND , DOSE - RESPONSE EFFICACY AND SAFETY STUDY OF SCH 900271 COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( FAMILIAL AND NONFAMILIAL ) OR MIXED HYPER LIPIDEMIA ( PRINCIPAL INVESTIGATOR , 2009 ) .", "label": "", "metadata": {}, "score": "45.536034"}
{"text": "MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , FOUR - PERIOD BALANCED CROSSOVER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN THERAPY IN", "label": "", "metadata": {}, "score": "46.021862"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL - GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DIFFERENT DOSES OF SLX-4090 IN COMBINATION WITH STATIN VS STATIN MONO - THERAPY IN PATIENTS WITH HYPERLIPIDEMIA PRINCIPAL INVESTIGATOR ( 2009 ) .", "label": "", "metadata": {}, "score": "46.363487"}
{"text": "Dejager S , Razac S , Foley JE , Schweizer A : Vildagliptin in drug - na\u00efve patients with type 2 diabetes : a 24-week , double - blind , randomized , placebo - controlled , multiple - dose study .", "label": "", "metadata": {}, "score": "46.839504"}
{"text": "The present study is an extension that was undertaken to evaluate dapagliflozin as long - term therapy in this population .Methods .This was a long - term extension ( total 102 weeks ) of a 24-week phase 3 , multicenter , randomized , placebo - controlled , double - blind , parallel - group trial .", "label": "", "metadata": {}, "score": "46.86242"}
{"text": "The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "47.183693"}
{"text": "A WORLDWIDE , MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0524A WHEN GIVEN AS MONOTHERAPY OR ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA .", "label": "", "metadata": {}, "score": "47.208908"}
{"text": "PubMed View Article .Strojek K , Yoon K , Hruba V , Elze M , Langkilde A , Parikh S : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomised , 24-week , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "47.294212"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , MULTICENTER LONG - TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID MODIFYING THERAPY ( PRINCIPAL INVESTIGATOR , 2015 ) .", "label": "", "metadata": {}, "score": "47.32611"}
{"text": "Commonly reported adverse reactions included nausea , diarrhoea , and injection site reactions .Vlad Hogenhuis , Senior Vice - President and Head , Cardiovascular , Metabolic and Neurosciences Franchise , GSK , said : \" While many phase III trials in type 2 diabetes are typically six months in duration , we set out to assess weekly - administered albiglutide for up to three years .", "label": "", "metadata": {}, "score": "47.697395"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - AND ACTIVE- CONTROLLED DOSE- RANGING STUDY WITH ACTIVE- CONTROLLED LONG TERM SAFETY PHASE TO ASSESS THE EFFICACY , SAFETY AND TOLERABILITY OF MK-6213 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA .", "label": "", "metadata": {}, "score": "47.733265"}
{"text": "A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO- AND ACTIVE - COMPARATOR - CONTROLLED , PARALLEL STUDY TO EVALUATE THE LIPID - ALTERING EFFICACY , SAFETY , AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA ( ELEVATED CHOLESTEROL AND TRIGLYCERIDES ) - ECHOCARDIOGRAPHIC SUBSTUDY ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "48.057037"}
{"text": "PubMed View Article .Circ J 2005 , 69 : 928 - 933 .PubMed View Article .Fukui M , Tanaka M , Shiraishi E , Harusato I , Hosoda H , Asano M , Kadono M , Hasegawa G , Yoshikawa T , Nakamura N : Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "48.152546"}
{"text": "A RANDOMIZED , DOUBLE - BLIND STUDY OF THE EFFICACY AND SAFETY OF REGN727 ADDED - ON TO ROSUVASTATIN VERSUS EZETIMIBE ADDED - ON TO ROSUVASTATIN VERSUS ROSUVASTATIN DOSE INCREASE IN PATIENTS WHO ARE NOT CONTROLLED ON ROSUVASTATIN ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "48.162636"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL GROUP , PHASE III STUDY TO ASSESS EFFICACY AND SAFETY OF AKR-963 THERAPY IN SUBJECTS WITH SEVERE HYERTRIGLYCERIDEMIA ( PRINCIPAL INVESTIGATOR , 2011 ) .", "label": "", "metadata": {}, "score": "48.239002"}
{"text": "PubMed View Article .Wilding JP , Woo V , Soler NG , Pahor A , Sugg J , Rohwedder K , Parikh S : Long - term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin : a randomized trial .", "label": "", "metadata": {}, "score": "48.488487"}
{"text": "PubMed View Article .Rahmoune H , Thompson PW , Ward JM , Smith CD , Hong G , Brown J : Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non - insulin - dependent diabetes .", "label": "", "metadata": {}, "score": "48.616302"}
{"text": "Yale JF , Bakris G , Cariou B et al ( 2013 ) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease .", "label": "", "metadata": {}, "score": "48.724823"}
{"text": "Bailey CJ , Gross JL , Pieters A , Bastien A , List JF ( 2010 )Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "48.93914"}
{"text": "Scott R , Wu M , Sanchez M , Stein P : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "48.941032"}
{"text": "PubMed View Article .Ferrannini E , Ramos SJ , Salsali A , Tang W , List JF : Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise : a randomized , double - blind , placebo - controlled , phase 3 trial .", "label": "", "metadata": {}, "score": "48.96949"}
{"text": "AN 8-WEEK , MULTICENTER , RANDOMIZED , DOUBLE - BLIND , FOUR - ARM , PARALLEL - GROUP COMPARING THE SAFETY AND EFFICACY OF ABT-143 TO SIMVASTATIN IN SUBJECTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2009 ) .", "label": "", "metadata": {}, "score": "49.16617"}
{"text": "Safety and tolerability .Pharmacoeconomics .Detailed Description .This was a Phase III , randomised , double blind , double dummy , multicentre , controlled , parallel group study of a 30 mg s.c .", "label": "", "metadata": {}, "score": "49.235847"}
{"text": "PubMed View Article .Bailey CJ , Gross JL , Pieters A , Bastien A , List JF : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "49.301804"}
{"text": "doi : 10 .1016/\u200bS0140 - 6736(13)60683 - 2 .Bode B , Stenlof K , Sullivan D , Fung A , Usiskin K ( 2013 ) Efficacy and safety of canagliflozin in older subjects with type 2 diabetes : a randomized trial .", "label": "", "metadata": {}, "score": "49.3769"}
{"text": "A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PARALLEL GROUP , 28 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE AND SIMVASTATIN CO - ADMINISTRATION VERSUS ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2002 ) .", "label": "", "metadata": {}, "score": "49.61088"}
{"text": "Bailey CJ , Gross JL , Hennicken D , Iqbal N , Mansfield TA , List JF ( 2013 ) Dapagliflozin add - on to metformin in type 2 diabetes inadequately controlled with metformin : a randomized , double - blind , placebo - controlled 102-week trial .", "label": "", "metadata": {}, "score": "49.801033"}
{"text": "A PHASE II , DOUBLE - BLIND , RANDOMIZED PLACEBO - CONTROLLED PARALLEL GROUP STUDY , EVALUATING THE EFFICACY AND SAFETY OF THREE DOSES OF RO4607381 COMBINED WITH PRAVASTATIN OVER A 12 WEEK PERIOD IN PATIENTS WITH LOW OR AVERAGE HDL - C LEVELS PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "49.84376"}
{"text": "May 2007 .Primary Completion Date .May 2007 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : . adult patients 30 - 75 years of age ; . treatment - naive , inadequately controlled diabetes despite diet and exercise , or inadequately controlled diabetes in patients on monotherapy or combination therapy ( maximum of 2 oral anti - hyperglycemic medications ) .", "label": "", "metadata": {}, "score": "50.264008"}
{"text": "May 2007 .Primary Completion Date .May 2007 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : . adult patients 30 - 75 years of age ; . treatment - naive , inadequately controlled diabetes despite diet and exercise , or inadequately controlled diabetes in patients on monotherapy or combination therapy ( maximum of 2 oral anti - hyperglycemic medications ) .", "label": "", "metadata": {}, "score": "50.264008"}
{"text": "Aschner P , Kipnes MS , Lunceford JK , Sanchez M , Mickel C , Williams - Herman DE , the Sitagliptin Study 021 Group : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "50.426716"}
{"text": "NICE , London .Karagiannis T , Paschos P , Paletas K , Matthews DR , Tsapas A ( 2012 ) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting : systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "50.432167"}
{"text": "A total of 546 patients were randomized to 1 of the 4 treatments .The completion rate for the 78-week double - blind extension period was lower for the placebo group ( 63.5 % ) than for the dapagliflozin groups ( 68.3 % to 79.8 % ) .", "label": "", "metadata": {}, "score": "50.443073"}
{"text": "A SECOND OPEN - LABEL EXTENSION OF A DOUBLE - BLIND , PARALLEL , PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA .", "label": "", "metadata": {}, "score": "50.77569"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PARRALEL - GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETC-1002 VS .PLACEBO IN PATIENTS WITH HYPERCHOLESTEROLEMIA RECEIVING ONGOING STATIN THERAPY ( PRINCIPAL INVESTIGATOR , 2014 ) .", "label": "", "metadata": {}, "score": "50.802303"}
{"text": "A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , \" FACTORIAL \" DESIGN , 12 WEEK STUDY TO EVALUATE THE EFFICACY OF SCH 58235 10 MG / DAY COADMINISTERED WITH MULTIPLE DOSES OF SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR 2001 ) .", "label": "", "metadata": {}, "score": "50.862083"}
{"text": "Diabetologia 55:1577 - 1596 , Erratum in 56:680 PubMed CrossRef .National Institute for Health and Clinical Excellence ( 2009 )Type 2 diabetes : newer agents for blood glucose control in type 2 diabetes .", "label": "", "metadata": {}, "score": "50.89979"}
{"text": "( PRINCIPAL INVESTIGATOR , 2001 ) .( PRINCIPAL INVESTIGATOR , 2001 ) .A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO AND ACTIVE - CONTROLLED , PARALLEL STUDY TO EVALUATE THE GLUCOSE AND LIPID - ALTERING EFFICACY AND SAFETY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES - EXTENSION ( PRINCIPAL INVESTIGATOR , 2001 ) .", "label": "", "metadata": {}, "score": "50.981377"}
{"text": "PubMed View Article .List JF , Woo V , Morales E , Tang W , Fiedorek FT : Sodium - glucose cotransport inhibition with dapagliflozin in type 2 diabetes .", "label": "", "metadata": {}, "score": "51.12383"}
{"text": "A PHASE III , DOUBLE BLIND , EFFICACY AND SAFETY STUDY OF ONE DOSE OF SCH 58235 10MG COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "51.239094"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , \" FACTORIAL \" DESIGN STUDY TO EVALUATE THE LIPID - ALTERING EFFICACY AND SAFETY OF EZETIMIBE / SIMVASTATIN COMBINATION TABLET IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR 2002 ) .", "label": "", "metadata": {}, "score": "51.258667"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , SEQUENTIAL - DESIGN STUDY TO EVALUATE THE LIPID - ALTERING EFFICACY AND TOLERABILITY OF MK-0354 IN PATIENTS WITH DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "51.32357"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , 1-YEAR EXTENSION OF THE PHASE IIA CLINICAL EFFICACY STUDY ( 026 - 01 ) TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "51.419167"}
{"text": "A 12 WEEK , DOUBLE - BLIND , PLACEBO - CONTROLLED , RANDOMIZED , MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CI-1027 IN PATIENTS WITH LOW HDL - C AND EITHER NORMAL OR ELEVATED TRIGLYCERIDES ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "51.42066"}
{"text": "A 76-WEEK , WORLDWIDE , MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA PRINCIPAL INVESTIGATOR ( 2008 ) .", "label": "", "metadata": {}, "score": "51.427094"}
{"text": "A SINGLE CENTRE , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ( T2D ) WHO ARE INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY .", "label": "", "metadata": {}, "score": "51.428726"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL GROUP , PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "51.44321"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , ACTIVE - CONTROLLED , MULTICENTER , CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE / ATORVASTATIN 10 MG/20MG FIXED - DOSE COMBINATION TABLET COMPARED TO CO - ADMINISTRATION OF MARKETED EZETIMIBE 10MG AND ATORVASTATIN 20MG IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2010 ) .", "label": "", "metadata": {}, "score": "51.673424"}
{"text": "Eligibility Criteria ICMJE .Inclusion Criteria : .Diagnosis of type 2 diabetes mellitus .On a stable ( for the last 3 months ) regimen of either metformin alone or metformin in combination with one additional acceptable oral antidiabetic ( OAD ) agent .", "label": "", "metadata": {}, "score": "51.74933"}
{"text": "A FOUR YEAR , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION AS PREVENTION OF CHD END POINTS ( RETINOPATHY )", "label": "", "metadata": {}, "score": "51.774246"}
{"text": "AN OPEN - LABEL EXTENSION OF A DOUBLE - BLIND , PARALLEL , PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA .", "label": "", "metadata": {}, "score": "51.905273"}
{"text": "PubMed View Article .Wilding JP , Norwood P , T'joen C , Bastien A , List JF , Fiedorek FT : A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers : applicability of a novel insulin - independent treatment .", "label": "", "metadata": {}, "score": "51.97333"}
{"text": "Strengths of this study include its design as a large trial that remained double - blinded throughout the long - term extension , unlike those conducted as open - label extensions .", "label": "", "metadata": {}, "score": "51.985516"}
{"text": "A RANDOMIZED , PLACEBO - CONTROLLED , DOSE ESCALATION STUDY TO EVALUATE THE SAFETY , TOLERABILITY , PHARMACOKINETICS , AND PHARMACODYNAMICS OF SINGLE AND REPEAT ORAL DOSES OF GSK256073A IN SUBJECT WITH BORDERLINE HIGH TO HIGH LDL CHOLESTEROL LEVELS PRINCIPAL INVESTIGATOR ( 2006 ) .", "label": "", "metadata": {}, "score": "52.32686"}
{"text": "GSK also released at the ADA additional analyses of data related to gastrointestinal adverse events from four pooled , placebo - controlled phase III studies , medication compliance data from three phase III studies and two subpopulation efficacy and safety analyses in Hispanic and African - American populations .", "label": "", "metadata": {}, "score": "52.380394"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL - GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE COMBINATION OF AEGR-733 ( FORMERLY BMS 201038 ) AND ATORVASTATIN 20 MG VS .", "label": "", "metadata": {}, "score": "52.465874"}
{"text": "References .Diabetes Care 2009 , 32 : 193 - 203 .PubMed View Article .Komoroski B , Vachharajani N , Feng Y , Li L , Kornhauser D , Pfister M : Dapagliflozin , a novel , selective SGLT2 inhibitor , improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "52.70289"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY OF SD-5613 SUSTAINED -RELEASE FORMULATION PROTOTYPES IN SUBJECTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2002 ) .", "label": "", "metadata": {}, "score": "52.821815"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP , 12 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0524B VERSUS ATORVASTATIN IN PATIENTS WITH MIXED HYPERLIPIDEMIA .", "label": "", "metadata": {}, "score": "52.861942"}
{"text": "AN EIGHT WEEK , DOUBLE - BLIND , PLACEBO - CONTROLLED , RANDOMIZED , MULTICENTER STUDY IN HYPERCHOLESTEROLEMIC PATIENTS TO DETERMINE THE EFFICACY AND SAFETY OF COMBINATION THERAPY WITH CI-1027 AND A STATIN ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "52.92141"}
{"text": "( PRINCIPAL INVESTIGATOR , 2012 ) .A DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , MULTICENTER STUDY TO EVALUATE LONG - TERM TOLERABILITY AND DURABLE EFFICACY OF AMG 145 ON LDL - C IN HYPERLIPIDEMIC SUBJECTS .", "label": "", "metadata": {}, "score": "53.053993"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP EVALUATION OF CERIVASTATIN 0.8 MG COMPARED TO CERIVASTATIN 0.4 AND PLACEBO ONCE DAILY IN PATIENTS WITH HYPERTRIGLYCERIDEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "53.252655"}
{"text": "PubMed View Article .Diabetes Care 2011 , 34 : 2015 - 2022 .PubMed View Article .Rosenstock J , Vico M , Wei L , Salsali A , List JF : Effects of dapagliflozin , an SGLT2 inhibitor , on HbA(1c ) , body weight , and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy .", "label": "", "metadata": {}, "score": "53.613407"}
{"text": "Ferrannini E , Ramos SJ , Salsali A , Tang W , List JF ( 2010 ) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise : a randomized , double - blind , placebo - controlled , phase 3 trial .", "label": "", "metadata": {}, "score": "53.759987"}
{"text": "A 16-WEEK , DOUBLE - BLIND , MULTICENTER STUDY TO EVALUATE THE EFFECT OF AVASIMIBE IN COMBINATION WITH ATORVASTATIN ON LIPIDS IN PATIENTS WITH TYPE IIA AND IIB DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "53.92169"}
{"text": "( 2012 ) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus .CPMP / EWP/1080/00 Rev. 1 .EMA , London .", "label": "", "metadata": {}, "score": "53.983364"}
{"text": "A PHASE 2B DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , PARALLEL GROUP , DOSE - RANGING STUDY TO ASSESS THE EFFICACY , SAFETY , AND TOLERABILITY OF PF-04950615 FOLLOWING MONTHLY AND TWICE MONTHLY SUBCUTANEOUS DOSING FOR SIX MONTHS IN HYPERCHOLESTEROLEMIC SUBJECTS ON A STATIN ( PRINCIPAL INVESTIGATOR , 2012 ) .", "label": "", "metadata": {}, "score": "53.98416"}
{"text": "MULTICENTER , RANDOMIZED , DOUBLE - BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXETIMIBE / SIMVASTATIN AND NIACIN ( EXTENDED RELEASE TABLET ) CO - ADMINISTERED IN PATIENTS WITH TYPE IIA ON TYPE IIB HYPERLIPIDEMIA .", "label": "", "metadata": {}, "score": "53.99115"}
{"text": "Bolen S , Feldman L , Vassy J , Wilson L , Yeh HC , Marinopoulos S , Wiley C , Selvin E , Wilson R , Bass EB , Brancati FL : Systematic review : comparative effectiveness and safety of oral medications for type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "54.11744"}
{"text": "RESEARCH COMPLETED TRIALS MULTICENTER , DOUBLE BLIND , TWO - ARM , PARALLEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HIGH DOSE SIMVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS - EXTENSION STUDY ( PRINCIPAL INVESTIGATOR , 1996 ) .", "label": "", "metadata": {}, "score": "54.356133"}
{"text": "A 6-WEEK , RANDOMIZED , OPEN - LABEL , COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROSUVASTATIN AND ATORVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN AFRICAN AMERICAN SUBJECTS ( PRINCIPAL INVESTIGATOR , 2002 ) .", "label": "", "metadata": {}, "score": "54.415123"}
{"text": "In addition , the mean baseline blood pressure was already near or at goal for patients with diabetes .The data from this 102-week trial demonstrate sustained glycemic and weight - loss benefits .", "label": "", "metadata": {}, "score": "54.41781"}
{"text": "Schernthaner G , Gross JL , Rosenstock J et al ( 2013 ) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea : a 52-week , randomized trial .", "label": "", "metadata": {}, "score": "54.43991"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , 1-YEAR EXTENSION OF THE PHASE II B DOSE SELECTION STUDY TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "54.50435"}
{"text": "The present report describes a long - term double - blind extension of this study to examine the effectiveness and safety of dapagliflozin add - on to metformin for 102 weeks in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "label": "", "metadata": {}, "score": "54.56051"}
{"text": "Abstract .Aims / hypothesis .The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with background metformin .", "label": "", "metadata": {}, "score": "54.63037"}
{"text": "The durability of type 2 diabetes therapy is typically limited by the natural history of the disease such that the progressive decline in \u03b2 - cell function superimposed upon insulin resistance restricts the continuing efficacy of interventions that are dependent on insulin production or insulin action [ 1 ] .", "label": "", "metadata": {}, "score": "54.688103"}
{"text": "Rosenstock J , Aggarwal N , Polidori D et al ( 2012 )Dose - ranging effects of canagliflozin , a sodium - glucose cotransporter 2 inhibitor , as add - on to metformin in subjects with type 2 diabetes .", "label": "", "metadata": {}, "score": "54.720978"}
{"text": "RESEARCH DESIGN AND METHODS- .Patients received counseling on diet and exercise .Additional antidiabetes agents were prohibited .Efficacy assessments included all randomized patients who received the double - blind study drug .", "label": "", "metadata": {}, "score": "54.72319"}
{"text": "Official Title ICMJE .A Randomized , Double - blind Study to Determine the Effect of GK Activator ( 2 ) on Efficacy ( HbA1c ) , Safety , Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus .", "label": "", "metadata": {}, "score": "54.77164"}
{"text": "Ferrannini E , Seman L , Seewaldt - Becker E , Hantel S , Pinnetti S , Woerle HJ ( 2013 )A phase IIb , randomized , placebo - controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "54.910484"}
{"text": "AN OBSERVATIONAL SAFETY FOLLOW - UP TRIAL OF THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS AND ALL - CAUSE MORTALITY IN SUBJECTS WHO PARTICIPATED IN SELECTED TORCETRAPIB / ATORVASTATIN CLINICAL TRIALS PRINCIPAL INVESTIGATOR ( 2007 ) .", "label": "", "metadata": {}, "score": "54.91183"}
{"text": "PubMed View Article .Rosenstock J , Vico M , Wei L , Salsali A , List JF : Effects of dapagliflozin , a sodium - glucose cotransporter-2 inhibitor , on hemoglobin A1c , body weight , and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy .", "label": "", "metadata": {}, "score": "54.985245"}
{"text": "United States , Bulgaria , Croatia , Guatemala , Hungary , Mexico , Poland A Randomized , Double - blind Study to Determine the Effect of GK Activator ( 2 ) on Efficacy ( HbA1c ) , Safety , Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus .", "label": "", "metadata": {}, "score": "55.1139"}
{"text": "PRINCIPAL INVESTIGATOR ( 2004 ) .A RANDOMIZED DOUBLE - BLIND , DOUBLE - DUMMY , PLACEBO - CONTROLLED , PHASE III STUDY TO ASSESS THE EFFICACY AND SAFETY OF 130MG OF RELIANT FENOFIBRATE , WITH AND WITHOUT FOOD , VERSUS A MATCHING PLACEBO , COMBINED WITH A LOW SATURATED - FAT DIET IN SUBJECTS WITH HYPERTRIGLYCERIDEMIA AND METABOLIC SYNDROME .", "label": "", "metadata": {}, "score": "55.202538"}
{"text": "PILOT DOSE - RANGING STUDY OF THE SAFETY AND EFFICACY OF SCH 58235 COMPARED TO PLACEBO AND LOVASTATIN IN PATENTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1997 ) .", "label": "", "metadata": {}, "score": "55.411423"}
{"text": "A WORLDWIDE , MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PARALLEL STUDY TO EVALUATE THE EFFICACY OF MK-0524 TO IMPROVE TOLERABILITY OF EXTENDED RELEASE NIACIN PRINCIPAL INVESTIGATOR ( 2006 ) .", "label": "", "metadata": {}, "score": "55.740986"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP EVALUATION OF CERIVASTATIN 0.8 MG COMPARED TO CERIVASTATIN 0.4 MG AND PLACEBO / PRAVASTATIN 40 MG ONCE DAILY IN PATENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1997 ) .", "label": "", "metadata": {}, "score": "55.78904"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DIAZOXIDE CHOLINE IN NON - DIABETIC HYPERTRIGLYCERIDEMIC SUBJECTS PRINCIPAL INVESTIGATOR ( 2008 ) .", "label": "", "metadata": {}, "score": "55.933872"}
{"text": "The safety population included patients who took at least one dose of the study drug ( double blind ) .Safety assessments included adverse events , clinical laboratory findings , 12-lead electrocardiograms , physical examination findings , vital signs , and hypoglycemic events .", "label": "", "metadata": {}, "score": "55.948074"}
{"text": "Sato K , Ozaki H , Salamon CM , Christopher RJ , Yamamoto M : Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys ( Abstract ) .", "label": "", "metadata": {}, "score": "56.0118"}
{"text": "AN OPEN - LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-475 IN SUBJECTS WITH HYPERCHOLESTEROLEMIA .PRINCIPAL INVESTIGATOR ( 2007 ) .A MULTICENTER RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY TO EVALUATE THE SAFETY , TOLERABILITY , PHARMACOKINETICS AND EFFICACY OF MBX-8025 IN MODERATELY OBESE HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT CONCOMITANT ATORVASTATIN .", "label": "", "metadata": {}, "score": "56.427704"}
{"text": "CONCLUSIONS- .Alogliptin monotherapy administered for 26 weeks to treatment - na\u00efve patients with type 2 diabetes produced significant and clinically meaningful improvements in A1C. Glycemic improvements with alogliptin were rapid , sustained , and independent of age , race , and sex .", "label": "", "metadata": {}, "score": "56.70346"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PARALLEL , MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN MONOTHERAPY COMPARED WITH SIMVASTATIN PLUS EZETIMIBE IN TYPE 2 DIABETIC PATIENTS TREATED WITH THIAZOLIDINEDIONES ( PRINCIPAL INVESTIGATOR , 2001 ) .", "label": "", "metadata": {}, "score": "56.753044"}
{"text": "A STUDY TO EVALUATE THE DEGREE OF CORRELATION BETWEEN HEPATIC ULTRASOUND , COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING AS METHODS TO DETECT POTENTIAL FAT INFILTRATION OF THE LIVER FOLLOWING 80 AND 160 MG BAY 13 - 9952 , OR PLACEBO DOSED ONCE DAILY FOR 28 DAYS IN HYPERCHOLESTEROLEMIC PATIENTS .", "label": "", "metadata": {}, "score": "56.78711"}
{"text": "Bosi E , Camisasca RP , Collober C , Rochotte E , Garber AJ : Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin .", "label": "", "metadata": {}, "score": "56.809948"}
{"text": "GSK presents new data for once - weekly Tanzeum / Eperzan ( albiglutide ) showing blood glucose lowering up to three years in type 2 diabetes .", "label": "", "metadata": {}, "score": "56.879036"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO CONTROLLED TRIAL OF ONCE PER DAY VS .SPLIT DOSING OF SEVELAMER HYDROCHLORIDE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "56.88417"}
{"text": "AN OPEN - LABEL EXTENSION OF A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF COMBINED OMACOR AND SIMVASTATIN THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS .", "label": "", "metadata": {}, "score": "57.00797"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PROSPECTIVE STUDY COMPARING THE SAFETY AND EFFICACY OF ABT-335 IN COMBINATION WITH ATORVASTATIN AND EZETIMIBE TO ATORVASTATIN IN COMBINATION WITH EZETIMIBE IN SUBJECTS WITH COMBINED ( ATHEROGENIC ) DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "57.11187"}
{"text": "DOUBLE BLIND STUDY OF A ATORVASTATIN COMPARED TO SIMVASTATIN IN LOWERING CHOLESTEROL IN PATIENTS WITH NON - INSULIN DEPENDENT DIABETES MELLITUS PATIENTS WITH DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR 1994 ) .", "label": "", "metadata": {}, "score": "57.19122"}
{"text": "Stenlof K , Cefalu WT , Kim K - A et al ( 2013 ) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise .", "label": "", "metadata": {}, "score": "57.204247"}
{"text": "This randomised , double - blind , four - arm , parallel - group , Phase 3 study was conducted at 169 centres in 22 countries between April 2010 and August 2012 .", "label": "", "metadata": {}, "score": "57.206154"}
{"text": "There were no apparent baseline differences across study groups to explain the variation in glycemic outcomes ; however , treatment - related weight reduction is likely to be a factor in enhancement of glucose reduction .", "label": "", "metadata": {}, "score": "57.397236"}
{"text": "( PRINCIPAL INVESTIGATOR , 2014 ) .A 4-WEEK , RANDOMIZED , PLACEBO - CONTROLLED , DOUBLE - BLIND , EFFICACY AND SAFETY STUDY OF HS-25 IN ADULTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "57.426346"}
{"text": "Official Title ICMJE .Phase 2 , Randomized , Double - Blind , Placebo - Controlled , Dose - Ranging , Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin .", "label": "", "metadata": {}, "score": "57.45305"}
{"text": "A 12-WEEK , RANDOMIZED , SEMI DOUBLE - BLINDED STUDY EVALUATING THE EFFECTS OF DAILY ORAL HIGH - DOSE ATORVASTATIN OR BMS-582949 ON ATHEROSCLEROTIC PLAQUE INFLAMMATION AS DETERMINED BY FDG - PET IN HIGH RISK ATHEROSCLEROTIC PATIENTS .", "label": "", "metadata": {}, "score": "57.454838"}
{"text": "Financial support for completion of this study and for data analysis was provided by Takeda Global Research & Development Center , Deerfield , Illinois .This study was presented at the 68th Annual Scientific Sessions of the American Diabetes Association , San Francisco , CA , 6 - 10 June 2008 , and at the 44th European Association for the Study for Diabetes Annual Meeting , Rome , Italy , 7 - 11 September 2008 .", "label": "", "metadata": {}, "score": "57.669834"}
{"text": "MULTICENTER , DOUBLE - BLIND , 4-ARM , PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN GEM 80 AND 160 MG IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1996 ) .", "label": "", "metadata": {}, "score": "57.83793"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP EVALUATION OF CERIVASTATIN COMPARED TO FLUVASTATIN 40MG AND PLACEBO DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1996 ) .", "label": "", "metadata": {}, "score": "57.867012"}
{"text": "A DOUBLE BLIND , RANDOMIZED , PLACEBO - CONTROLLED TRIAL TO EVALUATE THE EFFECTS OF SIMVASTATIN 80 MG A DAY ON STEROID HORMONE PRODUCTION IN MEN ( PRINCIPAL INVESTIGATOR , 1996 ) .", "label": "", "metadata": {}, "score": "58.061333"}
{"text": "\" The four phase III studies , entitled Harmony 1 , 2 , 4 and 5 , evaluated albiglutide in monotherapy as well as in combination with OADs , against placebo , insulin glargine and a thiazolidinedione ( pioglitazone ) .", "label": "", "metadata": {}, "score": "58.125954"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , 2 PERIOD , COMPLETE BLOCK , CROSSOVER STUDY TO EVALUATE THE EFFICACY OF L-654969 AND SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "58.19395"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL , MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH SIMVASTATIN IN THIAZOLIDINEDIONE - TREATED ( PIOGLITAZONE OR ROSIGLITAZONE )", "label": "", "metadata": {}, "score": "58.201668"}
{"text": "A MULTI - CENTER , 52 WEEK , OPEN - LABEL EXTENSION STUDY ( FROM STUDIES WEL-301 , WEL-302 , AND WEL-303 ) TO EVALUATE THE LONG - TERM SAFETY AND TOLERABILITY OF WELCHOL IN TYPE 2 DIABETIC PATIENTS PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "58.282352"}
{"text": "( PRINCIPAL INVESTIGATOR , 2002 ) .A RANDOMIZED , DOUBLE - BLIND , DOSE - RANGING , PLACEBO - CONTROLLED TRIAL TO DETERMINE THE LIPID - LOWERING EFFICACY AND SAFETY OF BMS 298585 ALONE AND IN COMBINATION WITH PRAVASTATIN IN SUBJECTS WITH MIXED DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR , 2002 ) .", "label": "", "metadata": {}, "score": "58.526917"}
{"text": "A DOUBLE BLIND , PLACEBO - CONTROLLED , RANDOMIZED PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0633 IN MEN WITH ATHEROSCLEROTIC DISEASE PRINCIPAL INVESTIGATOR ( 2006 ) .", "label": "", "metadata": {}, "score": "58.549606"}
{"text": "A MULTICENTER , EIGHT - WEEK , TREATMENT , SINGLE STEP TITRATION , OPEN - LABEL STUDY ASSESSING THE PERCENTAGE OF DYSLIPIDEMIC PATIENTS ACHIEVING LDL CHOLESTEROL TARGET WITH ATORVASTATIN STARTING DOSES OF 10 MG ; , 20 MG , 40 MG , AND 80MG ( PRINCIPAL INVESTIGATOR , 2002 ) .", "label": "", "metadata": {}, "score": "58.96456"}
{"text": "About this Article .Title .Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy : a randomised trial .", "label": "", "metadata": {}, "score": "58.999874"}
{"text": "Results for secondary efficacy measures and exploratory assessments are summarized in Table 1 .Overall incidences of adverse events ( 67.4 - 70.3 % ) and proportions of patients who discontinued because of adverse events ( 1.5 - 2.3 % ) were similar across treatment groups .", "label": "", "metadata": {}, "score": "59.011963"}
{"text": "Results .From the 546 originally randomized patients , 476 ( 87.2 % ) continued into the 78-week extension period .Of these , 339 ( 71.2 % ) completed the 102-week study ( Figure 1 ) .", "label": "", "metadata": {}, "score": "59.308624"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PARALLEL GROUP , PLACEBO - CONTROLLED , DOSE RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF GL262570 SODIUM TABLETS ( 2.5 MG , 5 MG , AND 7.5 MG ) ADMINISTERED AS A DAILY DOSE FOR 8 WEEKS IN SUBJECTS WITH DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "59.35382"}
{"text": "IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH RISK FOR CHD PRINCIPAL INVESTIGATOR ( 2007 ) .PRINCIPAL INVESTIGATOR ( 2007 ) .A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , \" CROSSOVER \" DESIGN STUDY TO EVALUATE THE LIPID - ALTERING EFFICACY AND SAFETY OF MK-0524B COMBINATION TABLET COMPARED TO MK-0524A + SIMVASTATIN COADMINISTRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA PRINCIPAL INVESTIGATOR ( 2007 ) .", "label": "", "metadata": {}, "score": "59.430153"}
{"text": "A MULTI - CENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL - GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY OR METFORMIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI - DIABETIC AGENTS PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "59.623535"}
{"text": "PubMed View Article .Komoroski B , Vachharajani N , Boulton D , Kornhauser D , Geraldes M , Li L , Pfister M : Dapagliflozin , a novel SGLT2 inhibitor , induces dose - dependent glucosuria in healthy subjects .", "label": "", "metadata": {}, "score": "59.745968"}
{"text": "PRINCIPAL INVESTIGATOR ( 2006 ) .A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , TITRATION STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF EZETIMIBE ADDED ON TO ATORVASTATIN 20MG VERSUS UP TITRATION TO ATORVASTATIN 40MG", "label": "", "metadata": {}, "score": "59.984283"}
{"text": "A PHASE III , MULTICENTER , DOUBLE - BLIND , CROSSOVER DESIGN STUDY TO EVALUATE LIPID - ALTERING EFFICACY AND SAFETY OF 1 G / 10 MG EXTENDED - RELEASE NIACIN / LAROPIPRANT / SIMVASTATIN COMBINATION TABLETS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR , 2011 ) .", "label": "", "metadata": {}, "score": "60.04753"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF CAT-2054 IN COMBINATION WITH ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2015 ) .", "label": "", "metadata": {}, "score": "60.186523"}
{"text": "During the 78-week extension , three deaths occurred ( Table 2 ): two in the dapagliflozin 2.5 mg group due to cardiopulmonary arrest and myocardial infarction , and one death in the placebo group due to malignant lung neoplasm .", "label": "", "metadata": {}, "score": "60.219505"}
{"text": "Inclusion Criteria : .Adult patients , 30 to 70 years of age inclusive at screening .Type 2 diabetes mellitus patients treated with stable metformin therapy for at least 12 weeks prior to screening ; metformin dose should not exceed the maximum dose specified in the label .", "label": "", "metadata": {}, "score": "60.308918"}
{"text": "A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , DOSE - RANGING STUDY TO ASSES THE EFFICACY , SAFETY , AND TOLERABILITY OF MK-0859 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA PRINCIPAL INVESTIGATOR ( 2006 ) .", "label": "", "metadata": {}, "score": "60.659573"}
{"text": "Keywords .Dapagliflozin metformin SGLT2 sodium - glucose cotransporter 2 glycemic control type 2 diabetes .Background .Treatment of type 2 diabetes often begins with lifestyle management and/or metformin [ 1 ] .", "label": "", "metadata": {}, "score": "60.741215"}
{"text": "A DOUBLE - BLIND , RANDOMISED , PARALLEL GROUP STUDY TO EVALUATE THE SAFETY , TOLERABILITY , AND EFFICACY OF TAK-475 ALONE OR CO - ADMINISTERED WITH ATORVASTATIN IN PATIENTS WITH PRIMARY DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "60.769035"}
{"text": "( PRINCIPAL INVESTIGATOR 1994 ) .A MULTICENTER , DOUBLE - BLIND , PLACEBO - CONTROLLED , 6-WEEK , DOSE - RANGING STUDY OF ONCE DAILY ATORVASTATIN IN PATIENTS WITH ELEVATED LDL - CHOLESTEROL .", "label": "", "metadata": {}, "score": "60.966377"}
{"text": "A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , PARALLEL GROUP STUDY OF LIPID - LOWERING EFFECTS OF XUEZHIKANG ( XZK )", "label": "", "metadata": {}, "score": "60.99671"}
{"text": "PHASE A : A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PARALLEL - DESIGN EXTENSION OF THE PHASE IIA CLINICAL EFFICACY STUDY ( 026 - 01 ) TO EVALUATE THE LIPID ALTERING EFFICACY OF MK0524A FORMULATION C COMPARED TO NIASPAN PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "61.011993"}
{"text": "One patient in the dapagliflozin 5 mg group had a serious adverse event of acute renal failure at day 624 due to urinary obstruction that resulted in discontinuation and resolved following prostatectomy .", "label": "", "metadata": {}, "score": "61.19056"}
{"text": "a Excluding data after rescue .Discussion .This treatment acts independently of \u03b2 - cell function or insulin sensitivity , thereby suggesting an alternative or complementary approach to currently available treatments and offering an additional therapeutic option throughout the natural history of type 2 diabetes .", "label": "", "metadata": {}, "score": "61.193443"}
{"text": "The proportion of patients who reported at least one event of hypoglycemia was similar across study groups ( Table 2 ) .Data are n ( % ) or n out of N ( % ) ; includes data after rescue .", "label": "", "metadata": {}, "score": "61.253517"}
{"text": "Pratley RE , Jauffret - Kamel S , Galbreath E , Holmes D : Twelve - week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes .", "label": "", "metadata": {}, "score": "61.359104"}
{"text": "A LONG - TERM , OPEN - LABEL , MULTI - CENTER TRIAL OF THE SAFETY AND EFFICACY OF NICOSTATIN IN PATIENTS WITH DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR , 1998 ) .", "label": "", "metadata": {}, "score": "61.36905"}
{"text": "The proportions of serious adverse events through 102 weeks were similar across dapagliflozin groups and the placebo group ( Table 2 ) .Few patients reported adverse events that led to discontinuation , and the proportion was similar in all treatment groups ( Table 2 ) .", "label": "", "metadata": {}, "score": "61.471092"}
{"text": "A YEAR 2 , LONG - TERM , OPEN - LABEL , SAFETY EXTENSION STUDY OF THE COMBINATION OF ABT-335 AND STATIN THERAPY FOR SUBJECTS WITH MIXED DYSLIPIDEMIA ) PRINCIPAL INVESTIGATOR ( 2007 ) .", "label": "", "metadata": {}, "score": "61.592487"}
{"text": "Effect of diuretics on the plasma lipid profile .Eur Heart J 13(Suppl G):61 - 67 .Nicolle LE , Capuano G , Fung A , Usiskin K ( 2013 ) Urinary tract infection ( UTI ) with canagliflozin ( CANA ) in subjects with type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "61.74163"}
{"text": "J Med Chem 50 : 2297 -2300 , 2007 .Clin Ther 30 : 499 -512 , 2008 .Lee B , Shi L , Kassel DB , Asakawa T , Takeuchi K , Christopher RJ : Pharmacokinetic , pharmacodynamic , and efficacy profiles of alogliptin , a novel inhibitor of dipeptidyl peptidase-4 , in rats , dogs , and monkeys .", "label": "", "metadata": {}, "score": "61.784348"}
{"text": "A STUDY TO INVESTIGATE THE SAFETY , TOLERABILITY , PHARMACOKINETICS AND PHARMACODYNAMICS OF ADMINISTERING MULTIPLE ORAL DOSES OF GSK1292263 ALONE AND WITH ATORVASTATIN ( PRINCIPAL INVESTIGATOR , 2010 ) .", "label": "", "metadata": {}, "score": "61.830982"}
{"text": "PHASE 3 MULTI - CENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED , PARALLEL GROUP EVALUATION OF THE EFFICACY , SAFETY , AND TOLERABILITY OF BOCOCIZUMAB ( PF-04950615 ) , IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS ( SPIRE 1 ) ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "61.927444"}
{"text": "This single - center , randomized , double - blind , placebo - controlled study will evaluate the effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy .", "label": "", "metadata": {}, "score": "62.015987"}
{"text": "Interventions : .Drug : Icatibant .Drug : Oral Placebo .Active Comparator : Randomized controlled - Tranexamic acid .Subjects received oral Tranexamic acid+ S.C. placebo .", "label": "", "metadata": {}, "score": "62.316322"}
{"text": "A LONG - TERM , OPEN - LABEL , SAFETY EXTENSION STUDY OF THE COMBINATION OF FENOFIBRIC ACID AND STATIN THERAPY FOR SUBJECTS WITH MIXED DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "62.435635"}
{"text": "This paper reports the follow - up to week 102 , with analysis of covariance model performed at 24 weeks with last observation carried forward ; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c , fasting plasma glucose ( FPG ) , and weight .", "label": "", "metadata": {}, "score": "62.909332"}
{"text": "Conclusions .Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c , FPG , and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone .", "label": "", "metadata": {}, "score": "62.984528"}
{"text": "CAT-2003 - 201 ( 2013 ) : A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED PILOT STUDY TO ASSESS THE SAFETY , EFFICACY AND PHARMACODYNAMICS OF CAT-2003 ALONE AND IN COMBINATION WITH A STATIN IN PATIENTS WITH HYPERLIPIDEMIA ( PATHWAYS 1 ) ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "63.029953"}
{"text": "ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL / HIGH TRIGLYCERIDE AND IMPACT ON GLOBAL HEALTH OUTCOMES 2007 PRINCIPAL INVESTIGATOR ( 2007 ) .A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL - GROUP STUDY TO EVALUATE LOW DOSES OF THE MTP - INHIBITOR AEGR-733 ON HEPATIC FAT ACCUMULATION AS MEASURED BY MAGNETIC RESONANCE SPECTROSCOPY PRINCIPAL INVESTIGATOR ( 2007 ) .", "label": "", "metadata": {}, "score": "63.107124"}
{"text": "A MULTI - CENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED , PARALLEL - GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN COMBINATION WITH ZETIA COMPARED TO ZETIA ALONE IN PATIENT WITH PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "63.15421"}
{"text": "IN OTHERWISE HEALTHY SUBJECTS WITH LOW HDL - C , MILDLY TO MODERATELY ELEVATED TRIGLYCERIDES , AND NORMAL LOW - DENSITY LIPOPROTEIN CHOLESTEROL PRINCIPAL INVESTIGATOR ( 2003 ) .", "label": "", "metadata": {}, "score": "63.216225"}
{"text": "MULTI - CENTER QUALIFICATION TRIAL FOR ENTRY INTO THE MULTI - CENTER , OPEN - LABEL TRIAL OF THE LONG - TERM SAFETY AND EFFICACY OF NIASPAN IN PATIENTS WITH PRIMARY HYPERLIPOPROTEINEMIA ( PRINCIPAL INVESTIGATOR 1994 ) .", "label": "", "metadata": {}, "score": "63.294285"}
{"text": "These strict rescue criteria ensured that even with a fully double - blinded long - term design , the participants in all groups were provided with adequate glycemic control .", "label": "", "metadata": {}, "score": "63.310047"}
{"text": "PLACEBO WHEN COADMINISTERED WITH ATORVASTATIN ( 10 OR 20 MG ) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2004 ) .A RANDOMIZED , DOUBLE - BLIND PLACEBO - CONTROLLED , 1-YEAR EXTENSION OF THE PHASE IIA ENDPOINT VALIDATION STUDY ( 015 - 01 ) TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET .", "label": "", "metadata": {}, "score": "63.3167"}
{"text": "Thus , patients whose HbA1c exceeded 7.5 % at 50 weeks or 7.0 % at 76 weeks received rescue therapy and were not included in the final efficacy analysis .", "label": "", "metadata": {}, "score": "63.32733"}
{"text": "PHASE II , MULTICENTER , DOUBLE - BLIND , PLACEBO CONTROLLED , PARALLEL GROUP , DOSE RANGING STUDY OF THE SAFETY , EFFICACY , AND TOLERABILITY OF ORAL CP - 529,414 SOFT - GEL CAPSULES IN SUBJECTS WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "63.67804"}
{"text": "Condition ICMJE .Diabetes Mellitus , Type 2 .Intervention ICMJE .Drug : aleglitazar .150 mcg orally daily , 16 weeks .Drug : metformin .", "label": "", "metadata": {}, "score": "64.01199"}
{"text": "A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES ( PRINCIPAL INVESTIGATOR , 2012 ) .", "label": "", "metadata": {}, "score": "64.295296"}
{"text": "Conclusions .Dapagliflozin added to metformin over 102 weeks showed sustained improved glycemic control , modest weight reduction , and no increased risk of hypoglycemia in type 2 diabetes inadequately controlled with metformin alone .", "label": "", "metadata": {}, "score": "64.317314"}
{"text": "DURABLE EFFECT OF PCSK9 ANTIBODY COMPARED WITH PLACEBO STUDY ( PRINCIPAL INVESTIGATOR , 2012 ) .EFFICACY , SAFETY , AND MECHANISM OF ACTION OF A SUPPLEMENT CAPSULE CONTAINING L. REUTERI CARDIOVIVA NCIMB 30242 ON MANAGING CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC ADULTS ( PRINCIPAL INVESTIGATOR , 2012 ) .", "label": "", "metadata": {}, "score": "64.479965"}
{"text": "The last observation carried forward method was used for imputing missing data ; testing was two - sided at a significance level of 0.05 .Continuous secondary efficacy analyses were performed as for the primary analysis , except that the baseline covariate corresponds with the tested end point .", "label": "", "metadata": {}, "score": "64.61474"}
{"text": "EFFICACY COMPARISON OF DIFFERENT FORMULATIONS OF PRAVASTATIN 40MG ( PRINCIPAL INVESTIGATOR , 1998 ) .A RANDOMIZED , DOUBLE - BLIND , PARALLEL , PLACEBO - CONTROLLED , MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN IN THERAPY IN PATIENTS WITH HYPERTRIGLYCERIDEMIA ( PRINCIPAL INVESTIGATOR , 1998 ) .", "label": "", "metadata": {}, "score": "64.624756"}
{"text": "A MULTI - CENTER , DOUBLE - BLIND , RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF : ATORVASTATIN 80MG AND ATORVASTATIN 40MGIN COMBINATION WITH EZETIMIBE 10MG IN PATIENTS NOT ADEQUATELY CONTROLLED ON 40MG OF ATORVASTATIN THERAPY .", "label": "", "metadata": {}, "score": "64.649765"}
{"text": "Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months .Any previous treatment with a thiazolidinedione or with a dual PPAR agonist .", "label": "", "metadata": {}, "score": "64.83894"}
{"text": "Data are means ( 95 % CI ) obtained from longitudinal repeated measures analyses .Data for HbA1c exclude patients who received rescue therapy to achieve the strict HbA1c requirements to remain in the trial .", "label": "", "metadata": {}, "score": "65.14175"}
{"text": "The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase .Secondary Outcome Measures : .", "label": "", "metadata": {}, "score": "65.370026"}
{"text": "WITH MEVACOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .A TWELVE WEEK MULTICENTER RANDOMIZED DOUBLE - BLIND PLACEBO - CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZD4522 ( 5,10,20,40 AND 80 MG )", "label": "", "metadata": {}, "score": "65.590614"}
{"text": "One patient on dapagliflozin 10 mg was diagnosed with breast cancer within the first year of enrollment .As shown in Table 3 , no clinically relevant mean changes from baseline in sodium , potassium , creatinine or blood urea nitrogen were apparent in any treatment group through week 102 .", "label": "", "metadata": {}, "score": "65.676605"}
{"text": "No skin lesions resembling those noted in nonclinical studies of other DPP-4 inhibitors were observed .Hypoglycemia was rare ( 1.5 - 3.0 % ) , and no hypoglycemic event was considered an adverse event or was severe enough to require assistance .", "label": "", "metadata": {}, "score": "65.89845"}
{"text": "Cefalu WT , Leiter LA , Yoon K - H et al ( 2013 ) Canagliflozin promotes body weight loss compared with glimepiride while providing glycaemic efficacy in subjects with type 2 diabetes on background metformin : 52-week findings from a randomised , double - blind trial .", "label": "", "metadata": {}, "score": "65.98401"}
{"text": "Those patients who remained in the study until year three continued to receive randomised treatment , as pre - specified in the study protocol , to further assess the efficacy and safety profile of albiglutide .", "label": "", "metadata": {}, "score": "65.99066"}
{"text": "A DOUBLE - BLIND , RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 50MG , 100MG OR PLACEBO WHEN CO - ADMINISTERED WITH ROSUVASTATIN ( 10 OR 20MG )", "label": "", "metadata": {}, "score": "66.020355"}
{"text": "Patients who completed the first 24-week period were eligible to continue in a long - term , double - blind extension period to 102 weeks .", "label": "", "metadata": {}, "score": "66.023926"}
{"text": "PRC-4016 ( 2013 ) : A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED 12-WEEK PHASE II PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRC-4016 600MG ONCE DAILY VERSUS PLACEBO IN STATIN - NA\u00cfVE OR STATIN - STABLE HYPERTRIGLYCERIDEMIC SUBJECTS ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "66.117355"}
{"text": "IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2008 ) .A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED STUDY TO EVALUATE THE EFFICACY , SAFETY , AND TOLERABILITY OF AVE5530 WHEN ADDED TO ONGOING STABLE STATIN THERAPY AT HIGH DOSES IN PATIENTS WITH SEVERE PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2008 ) .", "label": "", "metadata": {}, "score": "66.13477"}
{"text": "The mean HbA1c at baseline of all 546 randomized patients was 8.06 % .The reductions in HbA1c with dapagliflozin were dose dependent and statistically significant compared to placebo at week 102 ( Figure 2A ) .", "label": "", "metadata": {}, "score": "66.155045"}
{"text": "Adverse events from the most commonly observed categories occurred with similar or lower frequency in those given alogliptin versus placebo ( infection , 28.0 - 37.6 % ; gastrointestinal , 12.1 - 14.3 % ) .", "label": "", "metadata": {}, "score": "66.18848"}
{"text": "A better understanding of the relationship between glucosuria and genitourinary infections should be provided with ongoing safety analyses of the dapagliflozin trial program .Further study of the effects of dapagliflozin on metabolic surrogate markers will assist in discrimination of non - glycemic benefits .", "label": "", "metadata": {}, "score": "66.27878"}
{"text": "A detailed description of the 24-week methods was published previously [ 9 ] .The 78-week extension is described below .This double - blind , parallel - group , placebo - controlled multicenter study recruited patients from 80 sites in Argentina , Brazil , Canada , Mexico , and USA .", "label": "", "metadata": {}, "score": "66.53364"}
{"text": "A MULTICENTER , CONTROLLED , OPEN - LABEL EXTENSTION ( OLE ) STUDY TO ASSESS THE LONG - TERM SAFETY AND EFFICACY OF AMG 145 ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "66.57503"}
{"text": "Formal statistical testing was performed for the primary endpoint and used an analysis of covariance ( ANCOVA ) model at 24 weeks with the last observation carried forward approach for missing week 24 data excluding data after rescue [ 9 ] .", "label": "", "metadata": {}, "score": "66.60155"}
{"text": "WELCHOL LECTURE BUREAU CHART REVIEW PROGRAM ( PRINCIPAL INVESTIGATOR 2000 ) .A MULTICENTER , DOUBLE - BLIND , RANDOMIZED , PLACEBO- AND ACTIVE - COMPARATOR - CONTROLLED , PARALLEL STUDY TO EVALUATE THE LIPID - ALTERING EFFICACY , SAFETY , AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA ( ELEVATED CHOLESTEROL AND TRIGLYCERIDES ) .", "label": "", "metadata": {}, "score": "66.72778"}
{"text": "Experimental : Untreated patients at the baseline .Patients who were screened and found eligible but did not experience an angioedema attack , or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant Cholesterol & Lipid Clinical Trials .", "label": "", "metadata": {}, "score": "66.84671"}
{"text": "A PHASE II PIVOTAL STUDY TO EVALUATE EFFICACY AND SAFETY OF SCH 48461 IN SUBJECTS WITH HYPERCHOLESTEROLEMIA .( PRINCIPAL INVESTIGATOR 1993 ) .OPEN - LABEL STUDY OF FLUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN CLINICAL PRACTICE SETTINGS ( PRINCIPAL INVESTIGATOR 1993 ) .", "label": "", "metadata": {}, "score": "66.91404"}
{"text": "PRINCIPAL INVESTIGATOR ( 2007 ) .A 12-WEEK , MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PARALLEL - GROUP STUDY OF THE COMBINATION OF ABT-335 AND ROSUVASTATIN COMPARED TO ABT-335 AND ROSUVASTATIN MONOTHERAPY IN SUBJECTS WITH TYPE IIA AND IIB DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "66.91514"}
{"text": "Events of hypoglycemia were rare and were not severe .Evidence suggestive of genital infection was reported in 11.7 % to 14.6 % of dapagliflozin patients and 5.1 % of placebo patients , with one related discontinuation ( dapagliflozin 5 mg ) .", "label": "", "metadata": {}, "score": "67.11413"}
{"text": "A potential limitation of this study is the number of patients needing rescue medication in the placebo group .Although this might limit the statistical interpretation of durability of the glucose - lowering effect of dapagliflozin , it also emphasizes the clinical utility of dapagliflozin .", "label": "", "metadata": {}, "score": "67.468025"}
{"text": "PRINCIPAL INVESTIGATOR ( 2005 ) .A DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 ( 50MG OR 100 MG )", "label": "", "metadata": {}, "score": "67.643745"}
{"text": "IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .( PRINCIPAL COINVESTIGATOR , 1999 ) .A RANDOMIZED , DOUBLE - BLIND , MULTICENTER TRIAL TO COMPARE THE SHORT - TERM AND LONG - TERM EFFICACY AND SAFETY OF ZD4522 , SIMVASTATIN , AND PRAVASTATIN IN THE TREATMENT OF SUBJECTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "67.650475"}
{"text": "A DOUBLE - BLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LAPAQUISTAT ACETATE 100MG IN THE MORNING VS LAPAQUISTAT ACETATE 100MG IN THE EVENING VS LAPAQUISTAT ACETATE 50MG TWICE DAILY VS PLACEBO IN SUBJECTS WITH HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2007 ) .", "label": "", "metadata": {}, "score": "67.68892"}
{"text": "IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA .PRINCIPAL INVESTIGATOR ( 2006 ) .A DOUBLE - BLIND , RANDOMIZED , PLACEBO - CONTROLLED FACTORIAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 AND SIMVASTATIN ALONE AND IN COMBINATION IN SUBJECTS WITH HYPERCHOLESTEROLEMIA .", "label": "", "metadata": {}, "score": "67.77847"}
{"text": "A MULITICENTER , CONTROLLED , OPEN - LABEL EXTENSION ( OLE ) STUDY TO ASSESS THE LONG - TERM SAFETY AND EFFICACY OF AMG 145 ( PRINCIPAL INVESTIGATOR , 2013 ) .", "label": "", "metadata": {}, "score": "67.95602"}
{"text": "The data at 156 weeks presented at ADA is consistent with these results .Harmony 1 ( Abstract number : 2014 - 960-P ) is a three - year ( primary endpoint at one year ) , randomised , double - blind , placebo - controlled study which evaluated the efficacy and safety of albiglutide against placebo in patients inadequately controlled ( HbA1c 7 - 10 % ) on pioglitazone \u00b1 metformin .", "label": "", "metadata": {}, "score": "68.02134"}
{"text": "Serious adverse events occurred without relation to dose ( 12.5 mg , 3.8 % ; 25 mg , 0.8 % ; and placebo , 3.1 % ) and were considered unrelated to treatment .", "label": "", "metadata": {}, "score": "68.17308"}
{"text": "PRINCIPAL INVESTIGATOR ( 2009 ) .A DOUBLE - BLIND , RANDOMIZED , 12-MONTH , PARALLEL GROUP , FIXED DOSE , PLACEBO - CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AVE5530 25 MG / DAY AND 50 MG / DAY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2008 ) .", "label": "", "metadata": {}, "score": "68.30438"}
{"text": "MLA GlaxoSmithKline . \"GSK presents new data for once - weekly Tanzeum / Eperzan ( albiglutide ) showing blood glucose lowering up to three years in type 2 diabetes .", "label": "", "metadata": {}, "score": "68.71498"}
{"text": "A DOSE - RANGING STUDY OF NK-104 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA - SLIT LAMP EXAMINATION SUB - STUDY ( PRINCIPAL INVESTIGATOR 2001 ) .DOUBLE - BLIND , PLACEBO - CONTROLLED , DOSE RANGING TRIAL TO EVALUATE THE EFFICACY OF ATORVASTATIN ON BONE MINERAL DENSITY AND MARKERS FOR BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH DYLIPIDEMIA AND AT RISK FOR OSTEOPOROSIS ( PRINCIPAL INVESTIGATOR 2001 ) .", "label": "", "metadata": {}, "score": "68.938034"}
{"text": "United States , Bulgaria , Croatia , Guatemala , Hungary , Mexico , Poland Abstract .Background .Management of type 2 diabetes with metformin often does not provide adequate glycemic control , thereby necessitating add - on treatment .", "label": "", "metadata": {}, "score": "69.32089"}
{"text": "This was largely due to more patients in the placebo group ( 23.5 % ) withdrawing during the extension period for lack of efficacy , whereas withdrawals were 13.3 , 13.9 , and 7.6 % with dapagliflozin 2.5 mg , 5 mg , and 10 mg , respectively .", "label": "", "metadata": {}, "score": "69.33957"}
{"text": "Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "69.47369"}
{"text": "PRINCIPAL INVESTIGATOR ( 2006 ) .A MULTICENTER , RANDOMIZED , DOUBLE - BLIND , PROSPECTIVE STUDY COMPARING THE SAFETY AND EFFICACY OF FENOFIBRIC ACID AND ATORVASTIN CALCIUM THERAPY TO FENOFIBRIC ACID AND ATORVASTATIN CALCIUM MONOTHERAPY IN SUBJECTS WITH MIXED DYSLIPIDEMIA .", "label": "", "metadata": {}, "score": "69.478485"}
{"text": "PART B : A DOSE - RANGING STUDY TO EVALUATE THE TOLERABILITY OF MK-0524 AND ITS EFFECTS ON NIACIN - INDUCED FLUSHING IN LIPID CLINIC PATIENTS AND / OR NORMAL HEALTHY SUBJECTS PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "69.690796"}
{"text": "The study consisted of two parts : controlled phase and OLE phase .For the primary endpoint , Efficacy was determined by evaluating the differences in study outcomes using a Visual Analogue Scale for patients treated with icatibant and tranexamic acid .", "label": "", "metadata": {}, "score": "70.23325"}
{"text": "Signs or symptoms suggestive of UTI or genital infection responded to standard treatment typically without interruption of dapagliflozin therapy and rarely led to recurrence .No events of pyelonephritis were reported .", "label": "", "metadata": {}, "score": "70.34474"}
{"text": "Frequency : 3 x 2 capsules for 2 days , taken orally , 6 to 8 hours apart .Placebo Form : solution for injection , matched to icatibant for injection Single dose : 3 mL Frequency : one subcutaneous injection in the abdominal region .", "label": "", "metadata": {}, "score": "70.5251"}
{"text": "Funding .Keywords .Canagliflozin Metformin Sitagliptin Sodium glucose co - transporter 2 ( SGLT2 ) inhibitor Type 2 diabetes mellitus .Electronic supplementary material .", "label": "", "metadata": {}, "score": "70.64851"}
{"text": "A 6-WEEK , RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED STUDY TO ASSESS THE EFFICACYAND SAFETY OF ADD - ON EPANOVA TO STATIN THERAPY IN SUBJECTS WITH PERSISTENT HYPERTRIGLYCERIDEMIA AND HIGH RISK FOR CARDIOVASCULAR DISEASE ( PRINCIPAL INVESTIGATOR , 2012 ) .", "label": "", "metadata": {}, "score": "70.76721"}
{"text": "Positive for hepatitis B , hepatitis C or HIV infection .Clinical evidence of anemia .Symptomatic congestive heart failure ( New York Heart Association Class II - IV ) at screening .", "label": "", "metadata": {}, "score": "70.90326"}
{"text": "THIRD EXTENSION DOUBLE BLIND DOSE - RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG , 50UG , 100UG , AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG", "label": "", "metadata": {}, "score": "70.9325"}
{"text": "( PRINCIPAL INVESTIGATOR , 2002 ) .A 6-WEEK , OPEN - LABEL , DOSE - COMPARISON STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN , CERIVASTATIN , PRAVASTATIN , AND SIMVASTATIN IN SUBJECTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR , 2001 ) .", "label": "", "metadata": {}, "score": "71.0547"}
{"text": "Exploratory end points included changes in measures of pancreatic function ( fasting insulin , fasting proinsulin , and homeostasis model assessment of \u03b2 - cell function ) and lipid profiles .", "label": "", "metadata": {}, "score": "71.49177"}
{"text": "A low incidence of hypoglycemia occurred with alogliptin and with placebo .Weight gain is common among patients taking sulfonylureas and thiazolidinediones and may reduce treatment adherence ( 7 , 8 ) ; thus , the weight neutrality of alogliptin and other DPP-4 inhibitors may offer a therapeutic advantage ( 9 - 15 ) .", "label": "", "metadata": {}, "score": "71.601555"}
{"text": "IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2005 ) .AN OPEN - LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-475 100 MG IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA PRINCIPAL INVESTIGATOR ( 2005 ) .", "label": "", "metadata": {}, "score": "71.70373"}
{"text": "Subjects received S.C icatibant+ oral placebo .Icatibant Form : solution for injection , 3 mL , 10 mg / mL Single dose : 30 mg ( 3 mL ) .", "label": "", "metadata": {}, "score": "71.71701"}
{"text": "In summary , the efficacy and safety of alogliptin monotherapy were comparable with those of other DPP-4 inhibitors ( 9 - 15 ) .Alogliptin represents an effective treatment option whether given alone or in combination with antihyperglycemic agents from other classes .", "label": "", "metadata": {}, "score": "71.752846"}
{"text": "Intervention : Drug : GK Activator ( 2 ) .Placebo Comparator : 5 .Intervention : Drug : Placebo .Not Provided .Enrollment ICMJE .", "label": "", "metadata": {}, "score": "72.12303"}
{"text": "Intervention : Drug : GK Activator ( 2 ) .Placebo Comparator : 5 .Intervention : Drug : Placebo .Not Provided .Enrollment ICMJE .", "label": "", "metadata": {}, "score": "72.12303"}
{"text": "Fractures were reported by two patients ( 1.5 % ) each in the placebo , dapagliflozin 2.5 mg , and dapagliflozin 5 mg groups , and by three patients ( 2.2 % ) in the dapagliflozin 10 mg group during the 102-week study .", "label": "", "metadata": {}, "score": "72.22637"}
{"text": "Food and Drug Administration ( 2008 ) Guidance for industry .Diabetes mellitus : developing drugs and therapeutic biologics for treatment and prevention .FDA , Rockville , MD .", "label": "", "metadata": {}, "score": "72.27568"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "72.29967"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "72.29967"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "72.29967"}
{"text": "Conclusions / interpretation .Canagliflozin improved glycaemia and reduced body weight vs placebo ( week 26 ) and sitagliptin ( week 52 ) and was generally well tolerated in patients with type 2 diabetes on metformin .", "label": "", "metadata": {}, "score": "72.60625"}
{"text": "Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema ( HAE ) .Official Title ICMJE .Randomised Double Blind , Controlled , Parallel Group , Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema ( HAE ) .", "label": "", "metadata": {}, "score": "72.76626"}
{"text": "Drug : Tranexamic Acid .Drug : S.C. Placebo .Experimental : Controlled Open - label / laryngeal attack .Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase .", "label": "", "metadata": {}, "score": "72.80245"}
{"text": "A DOUBLE - BLIND , MULTI - CENTER STUDY OF THE SAFETY AND EFFICACY OF NIASPAN ( CONTROLLED - RELEASE NIACIN ) VERSUS GEMFIBROZIL PATIENTS WITH LOW LEVELS OF HIGH - DENSITY LIPOPROTEIN ( HDL ) CHOLESTEROL ( PRINCIPAL INVESTIGATOR , 1997 ) .", "label": "", "metadata": {}, "score": "73.15625"}
{"text": "Results .Overall AE and AE - related discontinuation rates were generally similar across groups , but higher with canagliflozin 100 mg .Genital mycotic infection and osmotic diuresis - related AE rates were higher with canagliflozin ; few led to discontinuations .", "label": "", "metadata": {}, "score": "73.44359"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "73.46292"}
{"text": "Drug : Tranexamic Acid . over encapsulated film tablet an anti - fibrinolytic agent , is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE .", "label": "", "metadata": {}, "score": "73.51675"}
{"text": "Harmony is the phase III clinical programme for albiglutide , comprising eight trials ( entitled Harmony 1 - 8 ) and involving over 5,000 patients .", "label": "", "metadata": {}, "score": "73.55206"}
{"text": "AN OPEN - LABEL , RANDOMIZED STUDY OF THE RELATIVE EFFICACY OF NICOSTATIN COMPARED TO SIMVASTATIN AND ATORVASTATIN ( PRINCIPAL INVESTIGATOR , 2000 ) .A DOUBLE - BLIND , PLACEBO - CONTROLLED , RANDOMIZED , DOSE - RANGING STUDY OF SD-5613 AS MONOTHERAPY AND IN COMBINATION THERAPY WITH ATORVASTATIN ( ASSESSMENT OF CHOLESTEROL REDUCTION BY AN INHIBITOR OF THE ILEAL BILE ACID TRANSPORTER SD-5613 ( ACRIIBAT ) ( PRINCIPAL INVESTIGATOR , 2000 ) .", "label": "", "metadata": {}, "score": "73.60132"}
{"text": "ATORVASTATIN / DIABETES EXTENSION STUDY ( PRINCIPAL INVESTIGATOR , 1995 ) .MULTICENTER , OPEN - LABEL , TRIAL OF THE LONG - TERM SAFETY AND EFFICACY OF NIASPAN IN PATIENTS WITH PRIMARY HYPERLIPOPROTEINEMIA ( PRINCIPAL INVESTIGATOR 1994 ) .", "label": "", "metadata": {}, "score": "74.066216"}
{"text": "Abbreviations .FPG : . fasting plasma glucose .HbA1c : . glycated hemoglobin .SGLT2 : . sodium - glucose cotransporter 2 .UTI : . urinary tract infection .", "label": "", "metadata": {}, "score": "74.39317"}
{"text": "Primary efficacy end point was mean change from baseline in A1C at the final visit .Overall , incidences of adverse events ( 67.4 - 70.3 % ) and hypoglycemia ( 1.5 - 3.0 % ) were similar across treatment groups .", "label": "", "metadata": {}, "score": "74.527054"}
{"text": "Experimental : 2 .Intervention : Drug : GK Activator ( 2 ) .Experimental : 3 .Intervention : Drug : GK Activator ( 2 ) .", "label": "", "metadata": {}, "score": "74.7245"}
{"text": "Experimental : 2 .Intervention : Drug : GK Activator ( 2 ) .Experimental : 3 .Intervention : Drug : GK Activator ( 2 ) .", "label": "", "metadata": {}, "score": "74.7245"}
{"text": "Placebo Comparator : Placebo .Intervention : Drug : Placebo .Not Provided .Completed .Enrollment ICMJE .Completion Date .May 2013 .Primary Completion Date .", "label": "", "metadata": {}, "score": "75.09221"}
{"text": "Severe , uncontrolled hypertension .Frequent hypoglycemia .Women of child - bearing potential .Gender .Both .Ages .18 Years to 70 Years .", "label": "", "metadata": {}, "score": "75.10837"}
{"text": "Data for weight , however , include patients who received rescue therapy ( pioglitazone ) , demonstrating the ability of dapagliflozin to attenuate weight gain by this antidiabetes medication .", "label": "", "metadata": {}, "score": "75.576385"}
{"text": "Despite increased surveillance for skin - related adverse events , their overall incidence remained low ( 12.5 % ) , albeit higher with alogliptin ( 12.8 - 15.2 % ) than with placebo ( 6.3 % ) , mostly because of pruritic events .", "label": "", "metadata": {}, "score": "75.73002"}
{"text": "Stable weight + /- 5 % for at least 12 weeks prior to screening .Exclusion Criteria : .Women who are pregnant , intending to become pregnant during the study period , currently lactating women , or women of child - bearing potential not using highly effective , medically approved birth control methods .", "label": "", "metadata": {}, "score": "75.81125"}
{"text": "Alogliptin is a novel , high - affinity , high - specificity DPP-4 inhibitor that produces rapid and sustained DPP-4 inhibition and significantly reduces postprandial plasma glucose concentrations in patients with type 2 diabetes ( 2 , 3 ) .", "label": "", "metadata": {}, "score": "76.67509"}
{"text": "1007/\u200bs00125 - 013 - 3039 - 1 ) contains peer - reviewed but unedited supplementary material , which is available to authorised users .References .", "label": "", "metadata": {}, "score": "76.79571"}
{"text": "Monotherapy , when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance .", "label": "", "metadata": {}, "score": "77.542015"}
{"text": "Small mean increases in hemoglobin and hematocrit , which were seen by about week 12 with dapagliflozin , remained stable thereafter .Data are means ( SD ) at baseline or mean changes [ SE ] from baseline at week 102 including data after rescue unless noted .", "label": "", "metadata": {}, "score": "77.77539"}
{"text": "Because metformin acts to improve insulin sensitivity [ 2 ] , the addition of therapy utilizing an insulin - independent pathway may be advantageous .Inhibition of sodium - glucose cotransporter 2 ( SGLT2 ) represents a novel approach to reduce hyperglycemia independently of insulin secretion or action [ 3 - 6 ] .", "label": "", "metadata": {}, "score": "78.11898"}
{"text": "IN PATIENTS WITH DYSLIPIDEMIA ( PRINCIPAL INVESTIGATOR , 2010 ) .A CLINICAL OUTCOMES STUDY OF DARAPLADIB VERSUS PLACEBO IN SUBJECTS WITH CHRONIC CORONARY HEART DISEASE TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS ( MACE ) .", "label": "", "metadata": {}, "score": "78.42881"}
{"text": "THROUGH USE OF THE BILE ACID SEQUESTRANT ACCEPTABILITY ( BASA ) SCALE IN GENERALLY HEALTHY SUBJECTS ( PRINCIPAL INVESTIGATOR , 2010 ) .A RANDOMIZED , SINGLE - BLIND , PLACEBO - CONTROLLED , SINGLE RESEARCH SITE , BILE ACID SEQUESTRANT ACCEPTABILITY ( BASA ) SCALE PILOT VALIDATION STUDY IN GENERALLY HEALTHY SUBJECTS ( PRINCIPAL INVESTIGATOR , 2010 ) .", "label": "", "metadata": {}, "score": "78.67786"}
{"text": "THE COMPELL STUDY : AN OPEN - LABEL , COMPARATIVE EFFICACY EVALUATION OF LIPID LEVELS WHEN TREATED WITH NIASPAN AND STATIN OR OTHER LIPID - MODIFYING THERAPIES PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "78.85208"}
{"text": "About Albiglutide .Albiglutide ( TanzeumTM / Eperzan \u00ae ) is a glucagon - like peptide-1 receptor agonist ( GLP-1 ) , a biological product for the treatment of type 2 diabetes , administered once - weekly using an injector pen supplied with a 5 mm 29-gauge thin - walled needle .", "label": "", "metadata": {}, "score": "78.88265"}
{"text": "The primary endpoint was change from baseline in HbA 1c at week 26 ; secondary endpoints included changes in HbA 1c ( week 52 ) and fasting plasma glucose ( FPG ) , body weight , and systolic blood pressure ( BP ; weeks 26 and 52 ) .", "label": "", "metadata": {}, "score": "79.28627"}
{"text": "In the US , albiglutide has been approved by the FDA ( April 2014 ) with the brand name TanzeumTM and is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "79.30287"}
{"text": "For abdominal attacks , the single primary symptom was abdominal pain .For cutaneous attacks , the single primary symptom was either skin swelling or skin pain , whichever was most severe .", "label": "", "metadata": {}, "score": "79.561295"}
{"text": "ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR 1993 ) .SECOND EXTENSION DOUBLE BLIND DOSE - RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG , 50UG , 100UG , AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG", "label": "", "metadata": {}, "score": "79.68381"}
{"text": "IMMEDIATE RELEASE NIACIN ( PRINCIPAL INVESTIGATOR 1994 ) .LONGTERM SAFETY AND EFFICACY OF NIACOR - SR TABLETS IN THE TREATMENT OF HYPERLIPIDEMIA ( PRINCIPAL INVESTIGATOR 1994 ) .", "label": "", "metadata": {}, "score": "79.924576"}
{"text": "The low rate of discontinuations due to adverse events indicates a favorable tolerability profile that makes this agent an important addition to the treatment armamentarium .", "label": "", "metadata": {}, "score": "80.057434"}
{"text": "Knowledge Center .Read our more detailed articles about specific areas of medicine , conditions , nutrition and forms of treatment .", "label": "", "metadata": {}, "score": "80.06444"}
{"text": "Experimental : TTP054 400 mg .Intervention : Drug : TTP054 .Experimental : TTP054 200 mg .Intervention : Drug : TTP054 .Experimental : TTP054 800 mg .", "label": "", "metadata": {}, "score": "80.41063"}
{"text": "Safety findings were summarized with descriptive statistics .RESULTS- .Baseline characteristics were similar among treatment groups .Participants had a mean \u00b1 SD age of 53.4 \u00b1 11.1 years and baseline A1C 7.9 \u00b1 0.08 % and were predominantly male ( 53.2 % ) and white ( 66.9 % ) .", "label": "", "metadata": {}, "score": "80.48567"}
{"text": "No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin .", "label": "", "metadata": {}, "score": "80.64012"}
{"text": "FENOFIBRATE AND CERIVASTATIN TRIAL OPTIMIZING RESPONSE ( FACTOR ) .A PHASE III DOUBLE - BLIND EFFICACY AND SAFETY STUDY OF SCH 58235 ( 10MG )", "label": "", "metadata": {}, "score": "81.02907"}
{"text": "Condition ICMJE .Hereditary Angioedema .Intervention ICMJE .Drug : Icatibant .Icatibant : a stable , synthetic decapeptide and specific BK B2 receptor antagonist .", "label": "", "metadata": {}, "score": "81.713776"}
{"text": "PubMed View Article .Klein BE , Klein R , Lee KE : Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam .", "label": "", "metadata": {}, "score": "81.71805"}
{"text": "\" Medical News Today .Contact our news editors .For any corrections of factual information , or to contact our editorial team , please see our contact page .", "label": "", "metadata": {}, "score": "81.88521"}
{"text": "Gender .Both .Ages .30 Years to 75 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "82.07193"}
{"text": "Gender .Both .Ages .30 Years to 75 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "82.07193"}
{"text": "For total body weight , when excluding data after rescue therapy , the adjusted mean value decreased from baseline with dapagliflozin ( -2.16 kg to -3.38 kg ) and with placebo ( -0.67 kg ) through week 102 .", "label": "", "metadata": {}, "score": "82.331474"}
{"text": "Other Name : Placebo .Drug : S.C. Placebo . solution for injection , matched to icatibant for injection .Other Name : Placebo .Study Arm ( s ) .", "label": "", "metadata": {}, "score": "82.5362"}
{"text": "Gender .Both .Ages .30 Years to 70 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Abstract .", "label": "", "metadata": {}, "score": "82.78077"}
{"text": "DOSE - RESPONSE EFFECTS OF ORAL NO-1886 ON LIPOPROTEINS IN SUBJECTS WITH DECREASED HDL - C LEVELS ( PRINCIPAL INVESTIGATOR , 1999 ) .PHASE II , DOSE - RESPONSE STUDY OF ORAL NO-1886 IN SUBJECTS WITH MARKED HYPERTRIGLYCERIDEMIA ( PRINCIPAL INVESTIGATOR , 1999 ) .", "label": "", "metadata": {}, "score": "83.40829"}
{"text": "Acknowledgements .The study team would like to acknowledge the patients for their participation and commitment during the study .We also thank the investigators and contributors from each study site .", "label": "", "metadata": {}, "score": "84.25162"}
{"text": "MediLexicon , Intl ., 16 Jun. 2014 .Web . 7 Feb. 2016 .APA GlaxoSmithKline .( 2014 , June 16 ) .\"", "label": "", "metadata": {}, "score": "84.66413"}
{"text": "TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms : cutaneous swelling , cutaneous skin , and abdominal pain .", "label": "", "metadata": {}, "score": "85.18021"}
{"text": "A RANDOMIZED , DOUBLE - BLIND , PLACEBO CONTROLLED STUDY OF SD-5613 AS MONOTHERAPY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA ( MONOTHERAPY ASSESSMENT OF REDUCING CHOLESTEROL ) [ MONARCH].", "label": "", "metadata": {}, "score": "85.18904"}
{"text": "The most frequently utilized boards were New England Institutional Review Board , Wellesley , Massachusetts ( 29 sites in the USA ) and IRB Services , Aurora , Ontario ( 19 sites in Canada ) .", "label": "", "metadata": {}, "score": "85.23042"}
{"text": "Limitations of Use .Tanzeum is not recommended as first - line therapy for patients inadequately controlled on diet and exercise .Tanzeum has not been studied in patients with a history of pancreatitis .", "label": "", "metadata": {}, "score": "86.09729"}
{"text": "PRAVASTATIN SPECIAL PATIENT POPULATION STUDY PRINCIPAL INVESTIGATOR ( 1992 ) .R.E.M. ( RESIN ENROBED METHOCEL )I STUDY ( PRINCIPAL INVESTIGATOR 1991 ) .R.E.M. ( RESIN ENROBED METHOCEL ) II STUDY ( PRINCIPAL INVESTIGATOR 1991 ) .", "label": "", "metadata": {}, "score": "86.241234"}
{"text": "Authors ' Affiliations .Life and Health Sciences , Aston University .Endocrine Division , Universidade Federal do Rio Grande do Sul .Global Biometric Services , Bristol - Myers Squibb , Parc de l'Alliance .", "label": "", "metadata": {}, "score": "86.38017"}
{"text": "STUDY CO - INVESTIGATOR ( 1991 ) .S.E.L.E.C.T. ( SELECOR 'S EFFECT LOWERING BP IN THOSE WITH ELEVATED CHOLESTEROL / TRIGLYCERIDES ) STUDY ( PRINCIPAL INVESTIGATOR 1991 )", "label": "", "metadata": {}, "score": "86.42227"}
{"text": "[ Time Frame : 2 days ] [ Designated as safety issue : No ] .The primary efficacy endpoint was Time to onset of symptom relief ( TOSR ) following treatment with either icatibant or tranexamic acid .", "label": "", "metadata": {}, "score": "86.49045"}
{"text": "History of active substance abuse ( including alcohol ) within the past 2 years or positive test result for drugs of abuse or alcohol prior to first dosing .", "label": "", "metadata": {}, "score": "86.79489"}
{"text": "POLARIS - PROSPECTIVE OPTIMISATION OF LIPIDS BY ATORVASTATIN OR ROSUVASTATIN INVESTIGATED IN HIGH - RISK SUBJECTS WITH HYPERCHOLESTEROLEMIA PRINCIPAL INVESTIGATOR ( 2004 ) .PULSAR - A PROSPECTIVE STUDY TO EVALUATE THE UTILITY OF LOW DOSES OF THE STATINS ATORVASTATIN AND ROSUVASTATIN PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "87.744736"}
{"text": "Prior intolerance to fibrate .Treatment with any anti - diabetic medication other than metformin in the last 12 weeks prior to screening and/or herbal / over - the - counter preparations that may affect glycemic control within 12 weeks prior to screening .", "label": "", "metadata": {}, "score": "89.05838"}
{"text": "PRINCIPAL INVESTIGATOR ( 2005 ) .A RANDOMIZED , DOUBLE - BLIND , PLACEBO - CONTROLLED ENDPOINT SELECTION AND QUESTIONNAIRE VALIDATION STUDY TO ASSESS THE NIACIN INDUCED FLUSHING CAUSED BY NIACIN PRINCIPAL INVESTIGATOR ( 2004 ) .", "label": "", "metadata": {}, "score": "89.468735"}
{"text": "ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA ( PRINCIPAL INVESTIGATOR 1992 ) .CHOLESTEROL SEQUESTRANT PHASE II STUDY ( CO - INVESTIGATOR 1992 ) .LIFIBROL ( A NOVEL CHOLESTEROL LOWERING AGENT )", "label": "", "metadata": {}, "score": "89.50099"}
{"text": "Known macular edema at screening or prior to screening visit .Uncontrolled hypertension despite stable ( for at least 4 weeks ) anti - hypertensive treatment .", "label": "", "metadata": {}, "score": "89.553185"}
{"text": "Tanzeum has been approved with a Risk Evaluation and Mitigation Strategy ( REMS ) , required by the FDA to ensure that the benefits of Tanzeum outweigh the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis .", "label": "", "metadata": {}, "score": "89.92047"}
{"text": "Experimental : Aleglitazar .Interventions : .Drug : aleglitazar .Drug : metformin .Placebo Comparator : Placebo .Interventions : .Drug : metformin .", "label": "", "metadata": {}, "score": "91.136444"}
{"text": "EFFICACY OF WELCHOL AS AN ADD - ON TO SIMVASTATIN ( PRINCIPAL INVESTIGATOR 2003 ) .EFFICACY OF WELCHOL AS AN ADD - ON TO PRAVASTATIN ( PRINCIPAL INVESTIGATOR 2003 ) .", "label": "", "metadata": {}, "score": "91.93642"}
{"text": "Available under Open Access This content is freely available online to anyone , anywhere at any time .Current Primary Outcome Measures ICMJE ( submitted : May 20 , 2014 ) .", "label": "", "metadata": {}, "score": "92.39958"}
{"text": "Editorial assistance was provided by Carolyn Carroll , PhD , and Ann L Davis , MPH , employees of Bristol - Myers Squibb .Competing interests .", "label": "", "metadata": {}, "score": "93.47907"}
{"text": "Data are means ( SD ) or means ( 95 % CI ) .a Adjusted mean change from baseline using longitudinal repeated measures , excluding data after rescue , except weight , which includes data after rescue .", "label": "", "metadata": {}, "score": "97.2842"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Bailey et al ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "98.91661"}
{"text": "Tanzeum has not been studied in patients with pre - existing severe gastrointestinal disease .Tanzeum has not been studied in combination with prandial insulin .", "label": "", "metadata": {}, "score": "100.26256"}
{"text": "Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .September 2013 .Primary Completion Date .September 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "102.05972"}
{"text": "CJB and JLG oversaw development of the manuscript .All authors made substantial contributions to conception and design , acquisition of data or analysis and interpretation of data , and revising the article for important content .", "label": "", "metadata": {}, "score": "103.66711"}
{"text": "The costs of publication of this article were defrayed in part by the payment of page charges .This article must therefore be hereby marked \" advertisement \" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact .", "label": "", "metadata": {}, "score": "111.54225"}
{"text": "DH is an employee of Bristol - Myers Squibb .NI , TAM , and JFL are employees and shareholders of Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "113.92557"}
{"text": "For more information , please read our terms of use .Copyright Medical News Today : Excluding email / sharing services explicitly offered on this website , material published on Medical News Today may not be reproduced , or distributed without the prior written permission of Medilexicon International Ltd.", "label": "", "metadata": {}, "score": "123.941055"}
